Classical Hodgkin lymphoma · 2 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin monotherapy Variant #01 | — | R 85 244 | 21d | 42.9 mo | — | 63 | R 5 370 365 PFS proxy | 1 |
Placebo Partial | — | — | — | 24.1 mo | — | — | — | 1 |
2 of 2 regimens shown